Digital health player Amalgam Rx launches with Type 2 diabetes app

Amalgam's first product is a prescription-only insulin-titration app, but the company's goal is to provide automated titration as a service for pharma companies that market basal insulin. (Amalgam Rx)

Amalgam Rx, a new company focusing on digital therapies for chronic diseases, launched Monday with the first FDA-cleared mobile app that automates the titration—or dose—of basal insulin for patients with Type 2 diabetes.

The prescription-only app, iSage Rx, is designed for patients who don’t use mealtime insulin or an insulin pump, the company said in a statement. It allows physicians to choose from a range of clinically validated basal insulin algorithms and adapt them for individual patients.

In addition to automating insulin titration, the app also includes behavioral, clinical and educational support for patients who are self-administering insulin. This includes supportive messages, video content on how to administer insulin and details on what to expect after being on insulin for certain periods of time, said founder and CEO Ryan Sysko.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Amalgam is recruiting for a proof-of-concept study in which 30 patients will use the app for 90 days, Sysko said. It will follow the change in patients’ glucose control in a bid to show how a completely automated titration app can support a patient on insulin.

Pharma companies are starting to realize the need to move beyond the pill, Sysko said. The industry is moving from a “pay-for-widget to a pay-for-outcomes model,” he said, and the only way to do this is to change the way care is delivered.

“People living with a chronic disease make a multitude of seemingly minor decisions every day that have a major impact on their condition," said founder and Chief Medical Officer Suzanne Clough in the statement.

“For healthcare providers, technology that makes patients’ self-management easier is the only way that we can scale to meet the growing need while also improving outcomes and reducing costs,” she said.

This isn’t Sysko and Clough’s first rodeo: The pair founded WellDoc, which markets the BlueStar app, a prescription-only diabetes management platform. And although Amalgam’s current focus is diabetes, the company plans to partner with life science and pharma companies on digital therapies for other chronic diseases.

Related: FDA clears integration of J&J, Welldoc tech for real-time diabetes management

And though Amalgam has launched its own titration app, the company is gearing up to create a “titration engine” that pharma partners may integrate into their own apps to support patients using their brands of insulin. To that end, the company has developed software development kits and application program interfaces.

“While we have developed an application or interface to test the efficacy of iSage, our ultimate goal is to provide insulin titration as a service,” Sysko said. “We want to enable the companies that are creating the operating systems for diabetes to easily integrate insulin titration.”

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.